Diabetes Drug

According to a report by diagnostic service provider Thyrocare, 49.43 per cent of the tested population in India exhibited abnormal blood glucose levels

Kamath revealed that a 20-year-old woman living in a city today has a 64.6 per cent chance of developing diabetes in her lifetime, while for young men, the risk is 55.5 per cent

Every year on November 14, we observe the World Diabetes Day (WDD) to increase awareness of diabetes, a chronic condition that affects millions of people worldwide

The Medicines and Healthcare products Regulatory Agency (MHRA) began a review of safety data for the class of drugs, known as GLP-1 receptor agonists, more than a year ago

Because the study was only observational, it cannot ascertain cause and effect between the drug and the impact on dementia risk. The scientists have called for clinical trials to now be carried out

Researchers say future study required to assess causality

Eli Lilly's Mounjaro, a blockbuster diabetes medication and a highly popular obesity treatment is still awaiting approval from CDSCO despite a SEC clearance

The Paris Olympics, which start on July 26, are an opportunity to showcase the technology - even though there is as yet no proof it can boost athletic performance

The sales of Novo Nordisk's Rybelsus tablet, used for diabetes treatment and weight reduction, more than doubled to Rs 363 crore this year from Rs 147 crore last year

Sanofi reported that in India, over 100 million individuals are grappling with type 2 diabetes and its associated complexities

Biomm SA develops and commercialises complex biotech and biosimilar drug products

Glenmark Pharmaceuticals launched a biosimilar version of liraglutide earlier this month, after getting the nod from the Drugs Controller General of India (DCGI)

Drug firm Lupin on Thursday said it has received approval from the US health regulator to market a generic medication to treat diabetes. The company has received approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application for Dapagliflozin and Saxagliptin tablets, the Mumbai-based drug maker said in a regulatory filing. The company's product is a generic equivalent of AstraZeneca AB's Qtern tablets, it added. This generic product will be manufactured at its Pithampur facility, the company said. Dapagliflozin and Saxagliptin tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As per IQVIA data, Dapagliflozin and Saxagliptin tablets had estimated annual sales of USD 5 million in the US market.

Drug, marketed under the brand name Lirafit, is priced at approximately Rs 100 for a standard daily dose of 1.2 mg

Glenmark Pharmaceuticals on Wednesday said it has launched a biosimilar of the popular antidiabetic drug, Liraglutide in India. The drug is being marketed under the brand name Lirafit following the approval from the Drug Controller General of India (DCGI), the company said in a statement. It is priced at around Rs 100 for a standard dose of 1.2mg (per day) and will lower the cost of therapy by approximately 70 per cent, the company claimed. Lirafit will be available only under prescription. "Clinical trials have shown that it helps improve glycemic control in adult type 2 diabetes mellitus patients along with atherosclerotic cardiovascular diseases (ASCVD) and obesity," Glenmark Pharmaceuticals President and Business Head India Formulations, Alok Malik said. Liraglutide has also proven to have a positive impact on cardiac and renal safety outcomes among patients in clinical trials, making it an effective choice of treatment for patients with type 2 diabetes mellitus, he added. "W

A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, US regulators announced on Wednesday. The US Food and Drug Administration approved Eli Lilly's Zepbound, or tirzepatide. The drug helped dieters lose about a quarter of their body weight, or 60 pounds (27 kilograms), in a recent study. Zepbound is the latest diabetes drug approved for weight loss, joining Novo Nordisk's Wegovy, a high-dose version of its diabetes treatment Ozempic. The FDA approved Lilly's drug for people who are considered obese, with a body mass index of 30 or higher, or those who are overweight with a related health condition, like high blood pressure, high cholesterol or diabetes. The drug should be paired with a healthy diet and regular exercise, the FDA said. In the US, at least 100 million adults and about 15 million children are considered obese. The drug tirzepatide in Zepbound and Mounjaro and semaglutide in Wegovy and Ozempic work by mimicking hormones that kick

The company said that Zituvimet has undergone quality testing for Nitrosamines and potential genotoxic impurities according to current FDA standards

The study involved 1,126 overweight and obese people who were randomly assigned to receive either metformin or a placebo within three days of testing positive for Covid-19

Drug major Cipla on Monday said it has inked a licensing pact with Novartis Pharma AG to manufacture and market Galvus range, used in the treatment of type 2 diabetes, from January 1, 2026. The Mumbai-based company has signed a perpetual license agreement with Novartis Pharma AG (Switzerland) to manufacture and market Galvus and Galvus combination brands, it said in a regulatory filing. "This deal is expected to further bolster Cipla's position in India as one of the top players in the diabetes category," it added. The agreement is subject to satisfaction of certain conditions precedent, the drug firm said. Galvus is one of the leading brands in the Dipeptidyl Peptidase-4 (DPP4) space and amongst the prominent brands in the oral diabetic medication category, the drug firm stated. On Monday, shares of Cipla ended 1.02 per cent up at Rs 901.85 apiece on the BSE.

Prices of 900 formulations are expected to increase to reflect annual change in WPI